Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBT (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBT for 11 consecutive years, with -$77.4 million as the latest value for Q4 2025.

  • Quarterly EBT fell 218.7% to -$77.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$136.8 million through Dec 2025, down 274.75% year-over-year, with the annual reading at -$139.5 million for FY2025, 80.84% down from the prior year.
  • EBT for Q4 2025 was -$77.4 million at Cartesian Therapeutics, down from -$19.5 million in the prior quarter.
  • The five-year high for EBT was $15.0 million in Q2 2024, with the low at -$196.7 million in Q4 2023.
  • Average EBT over 5 years is -$19.6 million, with a median of -$10.6 million recorded in 2023.
  • The sharpest move saw EBT surged 5505.67% in 2022, then plummeted 3608.62% in 2023.
  • Over 5 years, EBT stood at $12.4 million in 2021, then tumbled by 54.71% to $5.6 million in 2022, then tumbled by 3608.62% to -$196.7 million in 2023, then surged by 87.66% to -$24.3 million in 2024, then crashed by 218.7% to -$77.4 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$77.4 million, -$19.5 million, and -$20.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.